ACIU · AC Immune SA
Market Cap
$253.54M
Shares
99.43M
Volume · Oct 2
320.26K
Avg daily vol (3M)
202.12K
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$2.73
Open$2.84
Day$2.69–2.88
52W close$2.12–3.99
Avg vol 30d196K
Short int3.5M · 3.5% float · 25.0d
Short vol55%
DataJan 2020–Oct 2026
Metrics snapshot
Useful current figures from the complete screener profile.
Revenue (TTM)
$22.07M
Trailing 12 months
Net income (TTM)
−$54.40M
Trailing 12 months
Revenue growth YoY
+90.1%
Year over year
Operating margin
-252.2%
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
-25.4%
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+1.3%
Year over year · more shares
Price change (1Y)
-7.6%
Trailing year
Short interest
3.5%
Latest settlement · 25.0 days to cover
Equibles Rating
blended score · not investment adviceOverall
Strong Sell
SellHoldBuy
Technical
Neutral
Momentum
Very Weak
Sentiment
Bearish
Fundamentals
Limited
Quant / Vol
Very High
Market backdrop
VIX 15.3 · calm
Equity put/call 0.58
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
−3%
below
Price vs 50-day avg
+5%
above
RSI (14)
53
neutral
MACD trend
Negative
52-week position
32%
mid-range
Momentum
relative strength
1-month return
−7%
trailing
6-month return
−17%
trailing
YTD return
−13%
this year
Relative strength
−30%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $3 › 200d $3 — 200d above 50d
Institutional flow
Distributing
-10% holders QoQ · +6 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
3.50% of float · ▲ +5.4% MoM · 25.0 days cover
Volume signal
Reversal watch
High volume on a down day — possible exhaustion
Institution breadth
Steady
43 holders — mid 3-yr range
Squeeze score
78
high risk · 0–100
Fundamentals
Not enough data for a confident read.
Quant / Vol
risk profile
Volatility
75%
annualized · 1-yr
Max drawdown
−47%
past year
ATR
5.8%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Neutral
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
−3%
Neutral
Price vs 50-day avg
+5%
Bullish
RSI (14)
53
Neutral
MACD trend
Negative
Bearish
52-week position
32%
Neutral
Market signals — smart money & positioning
Bearish · 2 of 6
Trend (MA cross)
No cross
50d $3 › 200d $3 — 200d above 50d
Institutional flow
Distributing
-10% holders QoQ · +6 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
3.50% of float · ▲ +5.4% MoM · 25.0 days cover
Volume signal
Reversal watch
High volume on a down day — possible exhaustion
Institution breadth
Steady
43 holders — mid 3-yr range
Price context
position in its 52-week range
Range low $2
Now $3 · 32%
Range high $4
vs 200-day avg -3%
vs 50-day avg +5%
Illustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
ACIU
this stock
AC Immune SA
|
$253.54M | -13.2% | — | — | 3.5% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$133.37B | +11.3% | +46.2% | 30.7 | 1.9% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$81.13B | -4.8% | +20.8% | 19.5 | 2.5% |
|
MRNA
Moderna, Inc.
|
$79.40B | +544.3% | +4.3% | — | 8.2% |
|
CSLLY
Csl Ltd
|
$61.25B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Filings
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| ACIU | +8.1% | -7.0% | -17.4% | +4.0% | -13.2% |
| SPY | -0.2% | -0.5% | +12.2% | +0.9% | +12.9% |
| vs SPY | +8.4% | -6.5% | -29.6% | +3.1% | -26.1% |